Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ! A1 y( Y$ ?, \6 H: t4 R! J9 L
- n1 S# j$ W) L) @/ D: g4 k
8 M z Y+ G* d1 o6 p% m
Sub-category:
& g# |+ x& n2 n" Q2 r) VMolecular Targets
# K3 n$ S' a9 \- @7 ~+ B7 O4 S) {
. _4 e' }! C& f: s; N9 y
Category:
4 X+ v$ v3 A' X; k' A; C8 s/ UTumor Biology 1 a0 g: V5 M% B
/ {7 a: Z, e1 D. {
5 n5 O! s+ C/ c6 A* Y8 E0 fMeeting:% P; t9 _2 }! O+ o2 n# `7 q
2011 ASCO Annual Meeting 8 `$ `: Z% |! c5 o. i1 ]
( S4 n* B+ i9 |8 d- n- M% K q( d6 N' L) ~" u, ^1 \4 m* }
Session Type and Session Title:: M1 e0 P# |8 ?' D) L! [& H
Poster Discussion Session, Tumor Biology $ J, z5 L/ [+ h; S) \& [
- p. ]1 Q9 y% n- i9 I+ \9 x
u& ~/ h4 M& W+ K: C& N! ?0 W) xAbstract No:* o1 N- ~' E: x9 A p0 i% P2 |6 r! F0 d
10517 " [3 x2 A6 k; Y+ i$ t" g
* y4 ?, ~- z/ Y" ~9 q
" D) j% H% f" J) m; A) ]3 G% LCitation:9 E# z1 w+ @' N ]5 v
J Clin Oncol 29: 2011 (suppl; abstr 10517)
/ E, f* H2 B+ K d7 ]$ A5 |% ~7 H! W9 i0 [; o6 t
* F% y" \7 f' I/ BAuthor(s):" ^5 d; M% [" W
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
% B) p0 J) L0 i, V' h2 I
# M" j$ f4 ?1 ? Q3 u7 U& g$ e4 Y( h3 T6 j& L8 g% ?7 J' Z( n0 y5 @
, }7 w& e- [8 o, [, H# Y1 m
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.) S3 T2 H0 C, e+ K2 `
* f7 j( J! W; I5 W. z0 _3 xAbstract Disclosures
4 k3 Q' J# E4 Y6 t
' Z5 C5 P: L. F. R3 U4 x% |5 eAbstract:
G8 l" \3 e* w/ o7 ~" b$ n" }
' o1 @6 _4 s' f0 Q" g4 v
1 D# G N1 O* DBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
) l8 i8 X' T9 ]1 y+ j0 z, k r1 d/ T* R- G) y! p/ b
6 z) z- `! u. k; S
|
显身卡
